Ultragenyx Apazunersen Phase 3 Trial Fails, Additional Cost-Cutting Under Review
Efficacy Signal Disappeared in Aspire Phase 3
Ultragenyx Pharmaceutical (RARE)'s apazunersen (GTX-102) failed to meet its primary endpoint of change in Bayley-4 cognitive raw score and key secondary endpoint of Multidomain Response Index (MDRI) in the pivotal Phase 3 Aspire trial involving 129 Angelman syndrome patients. No supportive differences were observed between the treatment and control groups, and no efficacy was seen in the five individual components of the MDRI. The positive signals observed in Phase 1/2 were not replicated in the randomized controlled trial, which is a core factor in the asset value impairment.
Burden of Validating the UBE3A Target Strategy Increases
Apazunersen is an antisense oligonucleotide (ASO) administered intrathecally, designed to inhibit UBE3A-AS transcription and restore expression of the paternal UBE3A allele. Angelman syndrome results from loss of maternal UBE3A function, affecting approximately 60,000 patients in commercially accessible regions, but there is currently no approved curative therapy. Previous analyses projected apazunersen's peak annual sales to exceed USD 1.8 billion, making this failure more than just a single clinical trial setback for the company's valuation.
Regulatory Preferences Do Not Alleviate Development Risks
Apazunersen has received FDA Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, as well as EMA PRIME and Orphan Drug designations, but it remains in the pre-approval Phase 3 stage. The FDA placed the trial on hold in October 2020 following cases of lower limb weakness and lifted the hold in September 2021 after incorporating a dose reduction protocol. Safety in the Aspire trial was consistent with Phase 1/2, but the lack of efficacy means the accelerated regulatory pathways and designations cannot preserve approval potential.
A Setback for Competing ASOs and a Differentiation Opportunity
Ionis Pharmaceuticals (IONS)'s obudanersen (formerly ION582) also targets UBE3A-AS transcription and has completed Phase 3 REVEAL enrollment, with results expected in the second half of 2027. Oak Hill Bio's rugonersen (RO7248824) began Phase 3 BEACON dosing in June 2026. While the overall clinical risk for the class has increased, competing candidates differ in dose and potency, requiring independent outcome validation. Current patient treatment remains limited to symptomatic therapies such as antiepileptics and management of sleep and behavioral symptoms.
Investment Logic Shifts to Cost Structure
Ultragenyx is reevaluating the program's continuation and plans to consider significant additional cost reductions within the scope of protecting its approved product business. This follows the February 2026 announcement of a 130-employee or approximately 10% workforce reduction and USD 50 million restructuring costs. The company remains committed to its 2027 profitability target. The nearly 50% stock price drop the day after the announcement reflects a shift in valuation criteria from pipeline growth to execution on commercial revenue and cost control.
The failure of apazunersen's Phase 3 trial, which was valued at potential annual sales exceeding USD 1.8 billion, has shifted Ultragenyx's short-term value to depend more heavily on the scale of cost reductions and revenue growth from its existing approved products. From a research perspective, the lack of replication of cognitive and functional improvement signals from Phase 1/2 in a 129-patient randomized controlled trial necessitates revalidation of the UBE3A-AS inhibition strategy, including dose, potency, and endpoint design. While the result increases class risk for Phase 3 obudanersen and rugonersen, the approximately 60,000 Angelman syndrome patients and the absence of disease-modifying approvals maintain the commercial value of competing assets. In the medium to long term, the credibility of the 2027 profitability target hinges on how additional restructuring preserves R&D capabilities while reducing cash burn.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/ultragenyx-angelman-syndrome-drug-results-cost-cuts/829528/